Clinical Trials | June 16, 2026
Lilly’s Jaypirca cuts risk of disease progression or death by 45% in landmark trial
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
The study enrolled 639 patients, nearly 80% of whom had previously received a covalent BTK inhibitor
The company will unveil preliminary findings showing that Broncho-Vaxom was associated with a 28–38% reduction in respiratory tract infection rates at 12 months
Discussions focus on integrating ECG diagnostics into AI-enabled E-ICU Command Centre and expanding technology-driven healthcare access across underserved regions
MabionCD20 is a monoclonal antibody originally developed by Mabion as a biosimilar candidate to MabThera and Rituxan therapies
Phase 1 study to evaluate Siglec-6-targeted CAR-T therapy in relapsed or refractory AML and CLL patients, marking a major milestone for T-CURX’s scalable non-viral CAR-T platform
The new facility aims to accelerate formulation science and application-led research across pharma, biopharma, nutraceuticals, personal care, and home care segments
Patnaik stressed early diagnosis, rapid treatment, and aggressive surveillance as the backbone of elimination efforts
Postal ballot also clears remuneration proposal and new ESOP 2026 scheme, strengthening the company’s leadership and talent retention strategy
Acquisition strengthens integrated radiology and pathology capabilities, enhancing access to advanced diagnostics and preventive healthcare
New hit discovery service combines integrated DNA-Encoded Library screening, structural biology, biophysics, and X-ray crystallography
Subscribe To Our Newsletter & Stay Updated
